{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:48:04Z","timestamp":1795024084458,"version":"4.10.2"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"MOST | National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2302602"],"award-info":[{"award-number":["2021YFC2302602"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005089","name":"\u5317\u4eac\u5e02\u79d1\u5b66\u6280\u672f\u59d4\u5458\u4f1a | Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["Z210014"],"award-info":[{"award-number":["Z210014"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8235071080; 3247080250; 31570891; 31872736; 32022028; 81991505; 82201928"],"award-info":[{"award-number":["8235071080; 3247080250; 31570891; 31872736; 32022028; 81991505; 82201928"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Effective cancer immunotherapy requires enhancing tumor-targeted immune responses while limiting pathological inflammation, highlighting an urgent need for single agents that can achieve this balance. Here, we reported that Betrixaban (BT), an FDA-approved Factor Xa inhibitor, functioned as a dual immunomodulator that enhanced antitumor immune responses and suppressed hyperinflammation. BT enhanced innate tumor sensing and adaptive immune responses, partly via epigenetic modulation. In mouse tumor models, BT treatment inhibited tumor growth, accompanied by increased infiltration of activated CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells. Combining BT with immune checkpoint blockade synergistically enhanced antitumor efficacy. Additionally, BT attenuated pathological inflammation by reducing LPS-induced proinflammatory cytokine production and improving survival in a sepsis model. Mechanistically, BT induced a noncanonical, DNA-independent activation of the cGAS-STING pathway, triggering type I interferon signaling without provoking a full inflammatory cascade. These findings highlighted BT as a strategy to promote antitumor immunity while restraining inflammation, potentially improving cancer immunotherapy with reduced inflammatory toxicity.\n                  <\/jats:p>","DOI":"10.1038\/s44321-026-00429-1","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:05:46Z","timestamp":1778731546000},"page":"2213-2235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Betrixaban activates cGAS-STING to promote antitumor immunity without pathological inflammation"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1282-8975","authenticated-orcid":false,"given":"Yang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiRui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6495-4705","authenticated-orcid":false,"given":"Hanjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boming","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuailong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1120-1524","authenticated-orcid":false,"given":"Songying","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7444-729X","authenticated-orcid":false,"given":"Fuping","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"429_CR1","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0711-0","volume":"7","author":"YR Badran","year":"2019","unstructured":"Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M (2019) Concurrent therapy with immune checkpoint inhibitors and TNF\u03b1 blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer 7:226","journal-title":"J Immunother Cancer"},{"key":"429_CR2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005052","volume":"10","author":"GM Beasley","year":"2022","unstructured":"Beasley GM, Brown MC, Farrow NE, Landa K, Al-Rohil RN, Selim MA, Therien AD, Jung SH, Gao J, Boczkowski D et al (2022) Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma. J Immunother Cancer 10:e005052","journal-title":"J Immunother Cancer"},{"key":"429_CR3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1084\/jem.175.3.731","volume":"175","author":"A Bendelac","year":"1992","unstructured":"Bendelac A, Matzinger P, Seder RA, Paul WE, Schwartz RH (1992) Activation events during thymic selection. J Exp Med 175:731\u2013742","journal-title":"J Exp Med"},{"key":"429_CR4","doi-asserted-by":"crossref","unstructured":"Berraondo P, Cuesta R, Aranda F, Martinez-Ria\u00f1o A, Eguren-Santamaria I, Luri-Rey C, Risson A, Melero A, Gomis G, Melero I (2025) Immunocytokines and cytokine neutralization for cancer immunotherapy. Trends Cancer 11:790\u2013805","DOI":"10.1016\/j.trecan.2025.04.014"},{"key":"429_CR5","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1158\/0008-5472.CAN-14-1154","volume":"75","author":"AK Biktasova","year":"2015","unstructured":"Biktasova AK, Dudimah DF, Uzhachenko RV, Park K, Akhter A, Arasada RR, Evans JV, Novitskiy SV, Tchekneva EE, Carbone DP et al (2015) Multivalent forms of the notch ligand DLL-1 enhance antitumor T-cell immunity in lung cancer and improve efficacy of EGFR-targeted therapy. Cancer Res 75:4728\u20134741","journal-title":"Cancer Res"},{"key":"429_CR6","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1158\/2159-8290.CD-21-1181","volume":"12","author":"CS Chae","year":"2022","unstructured":"Chae CS, Sandoval TA, Hwang SM, Park ES, Giovanelli P, Awasthi D, Salvagno C, Emmanuelli A, Tan C, Chaudhary V et al (2022) Tumor-derived lysophosphatidic acid blunts protective type I interferon responses in ovarian cancer. Cancer Discov 12:1904\u20131921","journal-title":"Cancer Discov"},{"key":"429_CR7","doi-asserted-by":"crossref","unstructured":"Chen X, Zhao Y, Xie Y, Liu T, Wang H, Wang X, Guo X, You F (2025) Betrixaban activates cGAS and ERVs to promote dual nucleic-sensing antiviral immunity. EMBO Mol Med","DOI":"10.1101\/2025.08.08.669242"},{"key":"429_CR8","volume":"15","author":"H Choi","year":"2024","unstructured":"Choi H, Jeong SH, Sim\u00f3 C, Bakenecker A, Liop J, Lee HS, Kim TY, Kwak C, Koh GY, S\u00e1nchez S et al (2024) Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy. Nat Commun 15:9934","journal-title":"Nat Commun"},{"key":"429_CR9","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1172\/JCI86892","volume":"126","author":"L Corrales","year":"2016","unstructured":"Corrales L, McWhirter SM, Dubensky TWJr, Gajewski TF (2016) The host STING pathway at the interface of cancer and immunity. J Clin Investig 126:2404\u20132411","journal-title":"J Clin Investig"},{"key":"429_CR10","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/gutjnl-2024-332125","volume":"74","author":"E De Martin","year":"2025","unstructured":"De Martin E, Fulgenzi CAM, Celsa C, Laurent-Bellue A, Torkpour A, Lombardi P, D\u2019Alessio A, Pinato DJ (2025) Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events. Gut 74:1165\u20131177","journal-title":"Gut"},{"key":"429_CR11","volume":"10","author":"Y Di","year":"2024","unstructured":"Di Y, Wang Z, Xiao J, Zhang X, Ye L, Wen X, Qin J, Lu L, Wang X, He W (2024) ACSL6-activated IL-18R1-NF-\u03baB promotes IL-18-mediated tumor immune evasion and tumor progression. Sci Adv 10:eadp0719","journal-title":"Sci Adv"},{"key":"429_CR12","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.immuni.2023.11.008","volume":"56","author":"O Dufva","year":"2023","unstructured":"Dufva O, Gandolfi S, Huuhtanen J, Dashevsky O, Du\u00e0n H, Saeed K, Klievink J, Nygren P, Bouhlal J, Lahtela J et al (2023) Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers. Immunity 56:2816\u20132835.e2813","journal-title":"Immunity"},{"key":"429_CR13","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cell.2013.07.023","volume":"154","author":"P Gao","year":"2013","unstructured":"Gao P, Ascano M, Zillinger T, Wang W, Dai P, Serganov AA, Gaffney BL, Shuman S, Jones RA, Deng L et al (2013) Structure-function analysis of STING activation by c[G(2\u2019,5\u2019)pA(3\u2019,5\u2019)p] and targeting by antiviral DMXAA. Cell 154:748\u2013762","journal-title":"Cell"},{"key":"429_CR14","doi-asserted-by":"crossref","unstructured":"Guo X, Zhao Y, Rong X, Chen X, Wang X, Liu T, Xiao Y, Zou Y, Chu T, Wang X et al (2025) Phosphines-nitrogen-phosphines chelated CoCl2 is a novel therapeutic agent for pancreatic cancer. Res Square","DOI":"10.21203\/rs.3.rs-6476256\/v1"},{"key":"429_CR15","volume":"14","author":"X Guo","year":"2024","unstructured":"Guo X, Zhao Y, You F (2024) MOI is a comprehensive database collecting processed multi-omics data associated with viral infection. Sci Rep 14:14725","journal-title":"Sci Rep"},{"key":"429_CR16","doi-asserted-by":"crossref","first-page":"2410079","DOI":"10.1002\/adfm.202410079","volume":"34","author":"AR Hoover","year":"2024","unstructured":"Hoover AR, Liu K, Furrer C, Lam SSK, Anderson DW, Zhou Z, Yang J, Wong CF, Medcalf AD, Sun XH et al (2024) N-dihydrogalactochitosan drives conventional and alternative activations of STING to synergize type I IFN and IL-1\u03b2 productions for antitumor immunity. Adv Funct Mater 34:2410079","journal-title":"Adv Funct Mater"},{"key":"429_CR17","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D\u2019Angelo SP, Woo KM et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33:3193\u20133198","journal-title":"J Clin Oncol"},{"key":"429_CR18","doi-asserted-by":"crossref","unstructured":"Kang B, Zhao Y, Chen X, Fan R, You F, Cui Q (2025) Highly accurate prediction of broad-spectrum antiviral compounds with DeepAVC. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2025.02.15.638408v1","DOI":"10.1101\/2025.02.15.638408"},{"key":"429_CR19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003671","volume":"9","author":"KE Kortekaas","year":"2021","unstructured":"Kortekaas KE, Santegoets SJ, Tas L, Ehsan I, Charoentong P, van Doorn HC, van Poelgeest MIE, Mustafa DAM, van der Burg SH (2021) Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1\/PD-L1 immunotherapy. J Immunother Cancer 9:e003671","journal-title":"J Immunother Cancer"},{"key":"429_CR20","volume":"6","author":"S Kungwankiattichai","year":"2025","unstructured":"Kungwankiattichai S, Desai A, Koppinger S, Maziarz RT (2025) Immune-related adverse events associated with cancer immunotherapy. Medicine 6:100800","journal-title":"Medicine"},{"key":"429_CR21","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1021\/acs.accounts.0c00334","volume":"53","author":"L Li","year":"2020","unstructured":"Li L, Yang Z, Chen X (2020) Recent advances in stimuli-responsive platforms for cancer immunotherapy. Acc Chem Res 53:2044\u20132054","journal-title":"Acc Chem Res"},{"key":"429_CR22","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.immuni.2013.10.019","volume":"39","author":"X Li","year":"2013","unstructured":"Li X, Shu C, Yi G, Chaton CT, Shelton CL, Diao J, Zuo X, Kao CC, Herr AB, Li P (2013) Cyclic GMP-AMP synthase is activated by double-stranded DNA-induced oligomerization. Immunity 39:1019\u20131031","journal-title":"Immunity"},{"key":"429_CR23","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1016\/j.apsb.2021.12.010","volume":"12","author":"S Liang","year":"2022","unstructured":"Liang S, Li J, Zou Z, Mao M, Ming S, Lin F, Zhang Z, Cao C, Zhou J, Zhang Y et al (2022) Tetrahedral DNA nanostructures synergize with MnO(2) to enhance antitumor immunity via promoting STING activation and M1 polarization. Acta Pharmaceutica Sin B 12:2494\u20132505","journal-title":"Acta Pharmaceutica Sin B"},{"key":"429_CR24","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1158\/1078-0432.CCR-20-2564","volume":"27","author":"Y Liang","year":"2021","unstructured":"Liang Y, Hannan R, Fu YX (2021) Type I IFN activating type I dendritic cells for antitumor immunity. Clin Cancer Res 27:3818\u20133824","journal-title":"Clin Cancer Res"},{"key":"429_CR25","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-23-0118","volume":"29","author":"JJ Luke","year":"2023","unstructured":"Luke JJ, Piha-Paul SA, Medina T, Verschraegen CF, Varterasian M, Brennan AM, Riese RJ, Sokolovska A, Strauss J, Hava DL et al (2023) Phase I study of SYNB1891, an engineered E. coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies. Clin Cancer Res 29:2435\u20132444","journal-title":"Clin Cancer Res"},{"key":"429_CR26","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41422-020-00395-4","volume":"30","author":"M Lv","year":"2020","unstructured":"Lv M, Chen M, Zhang R, Zhang W, Wang C, Zhang Y, Wei X, Guan Y, Liu J, Feng K et al (2020) Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Res 30:966\u2013979","journal-title":"Cell Res"},{"key":"429_CR27","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ccell.2022.08.016","volume":"40","author":"JK Mandula","year":"2022","unstructured":"Mandula JK, Chang S, Mohamed E, Jimenez R, Sierra-Mondragon RA, Chang DC, Obermayer AN, Moran-Segura CM, Das S, Vazquez-Martinez JA et al (2022) Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses. Cancer cell 40:1145\u20131160.e1149","journal-title":"Cancer cell"},{"key":"429_CR28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41419-022-04664-5","volume":"13","author":"Y Messaoud-Nacer","year":"2022","unstructured":"Messaoud-Nacer Y, Culerier E, Rose S, Maillet I, Rouxel N, Briault S, Ryffel B, Quesniaux VFJ, Togbe D (2022) STING agonist diABZI induces PANoptosis and DNA mediated acute respiratory distress syndrome (ARDS). Cell Death Dis 13:269","journal-title":"Cell Death Dis"},{"key":"429_CR29","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1021\/acscentsci.3c01310","volume":"10","author":"DC Nguyen","year":"2024","unstructured":"Nguyen DC, Song K, Jokonya S, Yazdani O, Sellers DL, Wang Y, Zakaria A, Pun SH, Stayton PS (2024) Mannosylated STING agonist drugamers for dendritic cell-mediated cancer immunotherapy. ACS Cent Sci 10:666\u2013675","journal-title":"ACS Cent Sci"},{"key":"429_CR30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jtho.2023.11.018","volume":"19","author":"CL O\u2019Leary","year":"2024","unstructured":"O\u2019Leary CL, Pierce N, Patel SP, Naidoo J (2024) Immune-related toxicity in NSCLC: current state-of-the-art and emerging clinical challenges. J Thorac Oncol 19:395\u2013408","journal-title":"J Thorac Oncol"},{"key":"429_CR31","doi-asserted-by":"crossref","first-page":"eaba6098","DOI":"10.1126\/science.aba6098","volume":"369","author":"BS Pan","year":"2020","unstructured":"Pan BS, Perera SA, Piesvaux JA, Presland JP, Schroeder GK, Cumming JN, Trotter BW, Altman MD, Buevich AV, Cash B et al (2020) An orally available non-nucleotide STING agonist with antitumor activity. Science 369:eaba6098","journal-title":"Science"},{"key":"429_CR32","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1158\/2159-8290.CD-21-1671","volume":"12","author":"AJ Patel","year":"2022","unstructured":"Patel AJ, Warda S, Maag JLV, Misra R, Miranda-Rom\u00e1n MA, Pachai MR, Lee CJ, Li D, Wang N, Bayshtok G et al (2022) PRC2-inactivating mutations in cancer enhance cytotoxic response to DNMT1-targeted therapy via enhanced viral mimicry. Cancer Discov 12:2120\u20132139","journal-title":"Cancer Discov"},{"key":"429_CR33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","volume":"48","author":"SA Patel","year":"2018","unstructured":"Patel SA, Minn AJ (2018) Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity 48:417\u2013433","journal-title":"Immunity"},{"key":"429_CR34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.2017.75.1610","volume":"36","author":"SM Pollack","year":"2018","unstructured":"Pollack SM, Ingham M, Spraker MB, Schwartz GK (2018) Emerging targeted and immune-based therapies in sarcoma. J Clin Oncol 36:125\u2013135","journal-title":"J Clin Oncol"},{"key":"429_CR35","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1038\/s41591-025-03813-5","volume":"31","author":"K Rejeski","year":"2025","unstructured":"Rejeski K, Hill JA, Dahiya S, Jain MD (2025) Noncanonical and mortality-defining toxicities of CAR T cell therapy. Nat Med 31:2132\u20132146","journal-title":"Nat Med"},{"key":"429_CR36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.it.2024.11.014","volume":"46","author":"R Reschke","year":"2025","unstructured":"Reschke R, Sullivan RJ, Lipson EJ, Enk AH, Gajewski TF, Hassel JC (2025) Targeting molecular pathways to control immune checkpoint inhibitor toxicities. Trends Immunol 46:61\u201373","journal-title":"Trends Immunol"},{"key":"429_CR37","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","volume":"72","author":"B Sangro","year":"2020","unstructured":"Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR (2020) Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol 72:320\u2013341","journal-title":"J Hepatol"},{"key":"429_CR38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s43018-024-00889-9","volume":"6","author":"M Sanlorenzo","year":"2025","unstructured":"Sanlorenzo M, Novoszel P, Vujic I, Gastaldi T, Hammer M, Fari O, De Sa Fernandes C, Landau AD, G\u00f6cen-Oguz BV, Holcmann M et al (2025) Systemic IFN-I combined with topical TLR7\/8 agonists promotes distant tumor suppression by c-Jun-dependent IL-12 expression in dendritic cells. Nat Cancer 6:175\u2013193","journal-title":"Nat Cancer"},{"key":"429_CR39","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s43018-021-00213-9","volume":"2","author":"M Scheller","year":"2021","unstructured":"Scheller M, Ludwig AK, G\u00f6llner S, Rohde C, Kr\u00e4mer S, St\u00e4ble S, Janssen M, M\u00fcller JA, He L, B\u00e4umer N et al (2021) Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response. Nat Cancer 2:527\u2013544","journal-title":"Nat Cancer"},{"key":"429_CR40","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41575-024-01019-7","volume":"22","author":"E Triantafyllou","year":"2025","unstructured":"Triantafyllou E, Gudd CLC, Possamai LA (2025) Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management. Nat Rev Gastroenterol Hepatol 22:112\u2013126","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"429_CR41","volume":"13","author":"X Tu","year":"2022","unstructured":"Tu X, Chu TT, Jeltema D, Abbott K, Yang K, Xing C, Han J, Dobbs N, Yan N (2022) Interruption of post-Golgi STING trafficking activates tonic interferon signaling. Nat Commun 13:6977","journal-title":"Nat Commun"},{"key":"429_CR42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","volume":"9","author":"SJ Wang","year":"2023","unstructured":"Wang SJ, Dougan SK, Dougan M (2023) Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer 9:543\u2013553","journal-title":"Trends Cancer"},{"key":"429_CR43","volume":"19","author":"Y Wang","year":"2020","unstructured":"Wang Y, Luo J, Alu A, Han X, Wei Y, Wei X (2020) cGAS-STING pathway in cancer biotherapy. Mol Cancer 19:136","journal-title":"Mol Cancer"},{"key":"429_CR44","doi-asserted-by":"crossref","first-page":"24219","DOI":"10.1021\/acsnano.4c05657","volume":"18","author":"Z Wang","year":"2024","unstructured":"Wang Z, Miao F, Gu L, Zhang R, Ma Y, Li Y, Zheng J, Lin Z, Gao Y, Huang L et al (2024) Stimulator of interferon genes-activated biomimetic dendritic cell nanovaccine as a chemotherapeutic booster to enhance systemic fibrosarcoma treatment. ACS Nano 18:24219\u201324235","journal-title":"ACS Nano"},{"key":"429_CR45","volume":"617","author":"HH Wu","year":"2025","unstructured":"Wu HH, Leng S, Eisenstat DD, Sergi C, Leng R (2025) Targeting p53 for immune modulation: Exploring its functions in tumor immunity and inflammation. Cancer Lett 617:217614","journal-title":"Cancer Lett"},{"key":"429_CR46","volume":"10","author":"D Xiong","year":"2023","unstructured":"Xiong D, Zhang L, Sun ZJ (2023) Targeting the epigenome to reinvigorate T cells for cancer immunotherapy. Mil Med Res 10:59","journal-title":"Mil Med Res"},{"key":"429_CR47","first-page":"1","volume":"48","author":"C Yang","year":"2025","unstructured":"Yang C, Liao X, Zhou K, Yao Y, He X, Zhong W, Zheng D, Yang Y, Li M, Zhou M et al (2025) Multifunctional nanoparticles and collagenase dual loaded thermosensitive hydrogel system for enhanced tumor-penetration, reversed immune suppression and photodynamic-immunotherapy. Bioact Mater 48:1\u201317","journal-title":"Bioact Mater"},{"key":"429_CR48","volume":"37","author":"H Yuan","year":"2025","unstructured":"Yuan H, Qiu C, Wang X, Wang P, Yi L, Peng X, Xu X, Huang W, Bai Y, Wei J et al (2025) Engineering semiconducting polymeric nanoagonists potentiate cGAS-STING pathway activation and elicit long term memory against recurrence in breast cancer. Adv Mater 37:e2406662","journal-title":"Adv Mater"},{"key":"429_CR49","volume":"24","author":"M Zhang","year":"2025","unstructured":"Zhang M, Liu C, Tu J, Tang M, Ashrafizadeh M, Nabavi N, Sethi G, Zhao P, Liu S (2025) Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol Cancer 24:136","journal-title":"Mol Cancer"},{"key":"429_CR50","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/s41423-021-00669-w","volume":"18","author":"R Zhang","year":"2021","unstructured":"Zhang R, Wang C, Guan Y, Wei X, Sha M, Yi M, Jing M, Lv M, Guo W, Xu J et al (2021) Manganese salts function as potent adjuvants. Cell Mol Immunol 18:1222\u20131234","journal-title":"Cell Mol Immunol"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00429-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-026-00429-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00429-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:32:24Z","timestamp":1781505144000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-026-00429-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,15]]}},"alternative-id":["429"],"URL":"https:\/\/doi.org\/10.1038\/s44321-026-00429-1","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. None of the authors holds equity, stock options, or paid consultancy roles; serves in advisory capacities; owns intellectual property; or maintains any other commercial ties with entities that might benefit from this work. No author is a member of the editorial board of this journal, and there are no personal, political, or social interests that could reasonably be seen as influencing the research. All funding sources are disclosed in the Acknowledgments, and the funders had no involvement in study design, data collection, or analysis, the decision to publish, or manuscript preparation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}